It's Time for the Moderna Stock!

1-Moderna

Moderna expects to earn at least $ 18.4 billion this year from the COVID-19 vaccine mRNA-1273. Unlike Pfizer, Moderna will not have to share its profits with any other company. This brings Moderna to the best year in company history in 2021. Having lost money for more than 10 years, the company has been in the market to make enormous profits. You can also expect the company to transfer most of the earned wealth to projects under preparation! Moderna is currently planning a second major project to advance to late stage testing. The experimental cytomegalovirus (CMV) vaccine mRNA-1647 showed very promise in phase 2 clinical trials. The company believes that if the vaccine is approved, it could reach an annual sales volume of between $ 2 and $ 5 billion.

There are other exciting vaccines in the Moderna project line. The company plans to begin phase 1 studies on three flu vaccine candidates this year.

Preparations are underway for a phase 2 study of the Zika virus vaccine mRNA-1893 in 2021. Moderna is moving towards clinical testing this year with its other programs, including but not limited to experimental HIV vaccines and vaccines aimed at defeating the Epstein-Barr virus. The massive revenue from MRNA-1273 (Covid-19 Vaccine) will soon fund many more developments as well. Moderna CEO Stephane Bancel has made public that they want to expand the company to include up to 50 messenger RNA (mRNA) programs.

According to Moderna's historical performance, the stock is now extremely expensive. However, the company could benefit from strong and recurring revenues from the COVID-19 vaccine and subsequent vaccines for years to come.

We should not forget Moderna's potential to produce additional growth factors in the project line covering the next decade and beyond.   It's Time for the Moderna Stock! Source: https://www.fool.com/ You may also be interested in:

Is It Time To Buy For Pfizer Stock?